Convatec Group PLC CTEC.L
Composite 53/100; the shares have moved about 28% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Income ranks 36/100 — a moderate mark against it.
Quality ranks 60/100 — a slight point in its favour. Balance-sheet strength ranks 57/100 — a slight point in its favour. Growth ranks 55/100 — a slight point in its favour.
Income ranks 36/100 — a moderate mark against it. Valuation ranks 44/100 — a slight mark against it. Momentum ranks 49/100 — a slight mark against it.
What the company does Convatec Group PLC designs, makes and sells advanced wound care, ostomy care, continence care and infusion care products for chronic and acute conditions such as diabetes, cancer and spinal-cord injuries. It sells through pharmacies, hospitals and distributors across Europe, North America and other regions.
Key financials Convatec reports gross margin 56.3%, operating margin 18.1% and net margin 7.2% on 7.1% revenue growth, while EPS fell 36.5%. ROE is 10.9%, ROA 7.0% and ROCE 22.9%. Debt/equity is 1.00 with net debt/EBITDA at 2.47 and current ratio 1.53.
Stock health Quality pillar 62.5/100 and income pillar 73.7/100 are positives, but growth 40.0/100 and momentum 47.9/100 lag. RSI(14) is 69.30 and the stock is 11.05% below its 52-week high.
Price vs fair value The stock trades at a discount versus both our fair-value estimate and the consensus target. - Price is at a 6.70% discount to our fair-value estimate of 246.05 (internal estimate). - Price is at a 28.40% discount to the 12-month target of 296.10 based on 18 analysts (internal estimate). - Forward P/E of 14.41 and PEG of 0.12 are below long-run averages, suggesting undemanding multiples (internal estimate). - Net margin compression and negative EPS growth may explain part of the valuation gap (internal data).
Looking forward Forward P/E of 14.41 implies the market is pricing in modest near-term earnings recovery. Analysts’ 296.10 target suggests potential upside if margin stabilization and growth initiatives gain traction.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.